期刊文献+

COX-2选择性抑制剂塞来昔布联合PPAR-γ配体罗格列酮治疗子宫内膜癌的实验研究 被引量:4

Inhibiting Effect of Selective COX-2 Inhibitor Celecoxib Combined with PPAR-γ Ligand Rosiglitazone on Endometrial Carcinoma
下载PDF
导出
摘要 目的研究环氧合酶-2(COX-2)和过氧化物酶体增殖物激活受体-γ(PPAR-γ)蛋白在子宫内膜癌中的表达和临床意义,探讨COX-2选择性抑制剂塞来昔布联合PPAR-γ配体罗格列酮共同应用对于肿瘤细胞的干预效果。方法采用免疫组化方法,结合组织芯片技术,检测124例子宫内膜样腺癌、35例正常子宫内膜中COX-2和PPAR-γ蛋白的表达水平,结合临床病理因素进行分析。联合应用塞来昔布和罗格列酮处理RL95-2子宫内膜癌细胞,观察其对于肿瘤细胞生物学行为的影响和协同抑瘤作用。结果在子宫内膜样腺癌中,COX-2蛋白表达明显升高,PPAR-γ蛋白表达相对降低,两者具有负性相关关系。塞来昔布和罗格列酮可以有效抑制RL95-2子宫内膜癌细胞的增殖、侵袭、转移能力,联合应用抑制肿瘤的效果明显高于单独药物组。结论 COX-2的高表达和PPAR-γ的低表达与子宫内膜癌的发生、发展有密切关系,以COX-2和PPAR-γ为共同靶点,有望成为临床子宫内膜癌预防和治疗的重要手段和有效途径。 Objective To investigate the expression and clinical significance of COX‐2 and PPAR‐γin endometrial carcino‐ma (EEC) ,and to determine whether celecoxib combined with rosiglitazone ,a specific PPAR‐γ ligand ,synergistically inhibited growth ,invasion and metastasis of EEC cells.Methods Tissue microarray (TMA) and immunohistochemical staining were em‐ployed to detect the expression of COX‐2 and PPAR‐γ in EEC cells of 124 cases ,and normal endometrium samples (n=35) . Subsequently ,we examined the effects of celecoxib and rosiglitazone on the cell proliferation ,invasion and migration in endome‐trial carcinoma cell line RL95‐2.Results The expression of COX‐2 and PPAR‐γ protein was significantly increased and de‐creased ,respectively.Statistical analysis confirmed a significant negative relationship between COX‐2 and PPAR‐γ in EEC.Celecoxib and rosiglitazone inhibited proliferation ,invasion and migration of RL95‐2 cells.Moreover ,the inhibition effect was higher in the combination group than that in celecoxib or rosiglitazone alone group.Conclusion These data showed that up‐regulation of COX‐2 and down‐regulation of PPAR‐γmay play a crucial role in EEC development ,hence ,these markers may be used as novel therapeutic targets in patients with EEC.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2014年第6期619-625,共7页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金 安徽省自然科学基金资助项目(No.1208085MH152) 安徽省教育厅自然科学基金重点资助项目(No.KJ2014A160)
关键词 子宫内膜癌 环氧合酶-2 过氧化物酶体增殖物激活受体-Γ 塞来昔布 罗格列酮 endometrial carcinoma cyclooxygenase-2 peroxisome proliferator-activated receptor-γ Celecoxib Rosiglitazone
  • 相关文献

参考文献21

  • 1Gou H F,Chen X C,Zhu J,et al.Expressions of COX-2 and VEGF-C in gastric cancer:correlations with lymphangiogene-sis and prognostic implications[J].J Exp Clin Cancer Res,2011,30(1):14-21. 被引量:1
  • 2He Y F,Jin J,Wei W,et al.Overexpression of cyclooxygen-ase-2 in noncancerous liver tissue increases the postoperativerecurrence of hepatocellular carcinoma in patients with hepati-tis B virus-related cirrhosis[J].Can J Gastroenterol,2010,24(7):435-440. 被引量:1
  • 3Zhang J,Luo J,Ni J,et al.MMP-7 is upregulated by COX-2and promotes proliferation and invasion of lung adenocarcino-ma cells[J].Eur J Histochem,2014,58(1):2262-2262. 被引量:1
  • 4Fukazawa E M,Baiocchi G,Soares F A,et al.COX-2,EGFR,and ERBB-2 expression in cervical intraepithelial neoplasiaand cervical cancer using an automated imaging system[J].IntJ Gynecol Pathol,2014,33(3):225-234. 被引量:1
  • 5Jana D,Sarkar D K,Ganguly S,et al.Role of Cyclooxygenase2(COX-2)in prognosis of breast cancer[J].Indian J Surg On-col,2014,5(1):59-65. 被引量:1
  • 6Dicitore A,Caraglia M,Gaudenzi G,et al.Type I interferon-mediated pathway interacts with peroxisome proliferator acti-vated receptor-y(PPAR-y):at the cross-road of pancreaticcancer cell proliferation[J],Biochim Biophys Acta,2014,1845(1):42-52. 被引量:1
  • 7Yokoyama Y,Mizunuma H.Peroxisome proliferator-activatedreceptor and epithelial ovarian cancer[J].Eur J Gynaecol On-col,2010,31(6):612-615. 被引量:1
  • 8Panza A,Votino C?Gentile A,et al.Peroxisome proliferator-activated receptor y-mediated induction of microRNA-145 op-poses tumor phenotype in colorectal cancer[J].Biochim Bio-phys Acta,2014,1843(6):1225-1236. 被引量:1
  • 9Papi A,De Carolis S,Bertoni S,et al.PPARy and RXR lig-ands disrupt the inflammatory cross-talk in the hypoxic breastcancer stem cells niche[J].J Cell Physiol,2014,229(11):1595-1606. 被引量:1
  • 10Marques A R,Espadinha C,Frias M J,et al.Underexpressionof peroxisome proliferator-activated receptor(PPAR)gammain PAX8/PPAR gamma-negative thyroid tumours[J].Br J Cancer,2004,91(4):732-738. 被引量:1

二级参考文献23

  • 1Lee KR. Atypical polypoid adnomyoma of the endometrium associated with adenomyomatosis and adenocarcinoma. Gynecol Oncol, 1993, 51: 416. 被引量:1
  • 2Duska LR, Garrett A, Rueda BR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol, 2001, 83: 388-393. 被引量:1
  • 3Yamakawa Y, Hirai Y, Nakayama K, et al. Clinicopathological analysis of endometrial carcinoma in younger women. Nippon Sanka Fujinka Gakkai Zasshi, 1991, 43: 45-50. 被引量:1
  • 4Quinn MA, Kneale BJ, Fortune DW. Endometrial carcinoma in premenopausal women: a clinicopathological study. Gynecol Oncol, 1985, 20: 298-306. 被引量:1
  • 5Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol, 1984, 64: 417-420. 被引量:1
  • 6Silverberg SG. Problems in the diferential deagnosis of endometrial hyperplasia and carcinoma. Mod Pathol, 2000, 13: 309-327. 被引量:1
  • 7Kim YB, Holschneider CH, Ghosh K, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer, 1997, 79: 320-327. 被引量:1
  • 8Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol, 1997, 90: 434-440. 被引量:1
  • 9Colafranceschi M, Taddei GL, Scarselli G, et al. Clinico-pathological profile of endometrial carcinoma in young women (under 40 years of age). Eur J Gynaecol Oncol, 1989, 10: 353-356. 被引量:1
  • 10Fukunage M, Endo Y, Ushigome S, et al. Atypical polypoid adenomyomas of the uterus. Histopathology, 1995, 27: 35-42. 被引量:1

共引文献14

同被引文献76

  • 1俞梅,沈铿,杨佳欣,黄惠芳,吴鸣,潘凌亚,郎景和,连利娟.高分化子宫内膜样癌及子宫内膜重度不典型增生患者孕激素治疗的临床分析[J].中华妇产科杂志,2006,41(4):242-245. 被引量:28
  • 2Zhang X H, Huang D P,Guo G L,et al. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast caneerD~. BMC Cancer, 2008,8 : 4. 被引量:1
  • 3Wang M T, Honn K V, Nie D. Cyelooxygenases, prostanoids, and tumor progression[J]. Cancer Metastasis Rev, 2007, 26 (3) :525-534. 被引量:1
  • 4Xin X, Majumder M, Girish G V, et al. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogene- sis and metastasis to the lungs and lymph nodes in a breast cancer model[J]. Lab Invest,2012,92(8):1115-1128. 被引量:1
  • 5Shi X,Chen G,Xing H,et al. VEGF-C,VEGFR-3 and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro [J]. Oncol Rep, 2007,18 (1) : 241-247. 被引量:1
  • 6Shi X Y, Xi L, Weng D H, et al. Clinicopathologieal signifi- cance of VEGF-C, VEGFR-3 and cyclooxygenase-2 in early- stage cervical cancer[J]. IJBS,2008,4(1) :58 63. 被引量:1
  • 7Morita Y, Morita N, Hata K J, et al. Cyclooxygenase 2 ex- pression is associated with vascular endothelial growth factor- C and lymphnode metastasis in human oral tongue Cancer[J]. Original Article,2014,117(4) :502 510. 被引量:1
  • 8Iwata C,Kano M R,Komuro A,et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogene- sis[J]. Cancer Res,2007,67(21) :10181-10189. 被引量:1
  • 9Hollingshead H E,Borland M G,Billin A N,et al. Ligand activation of peroxisome proliferatot~activated receptor-beta/delta(PPARbeta/ delta)and inhibition of cyclooxygenase 2 (COX-2)attenuate colon carcinogenesis through independent signaling mechanisms[J]. Carci- nogenesis, 2008,29 (1), 169 176. 被引量:1
  • 10Gou H F,Chen X C,Zhu J,et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogene- sis and prognostic implications[J]. J Exp Clin Cancer Res, 2011,30(2)=14 21. 被引量:1

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部